119 related articles for article (PubMed ID: 28705006)
1. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Cinar P; Ko AH
Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
[TBL] [Abstract][Full Text] [Related]
2. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer.
Tang CY; Yang SH; Li CP; Su YY; Chiu SC; Bai LY; Shan YS; Chen LT; Chuang SC; Chan DC; Yen CJ; Peng CM; Chiu TJ; Chen YY; Chen JS; Chiang NJ; Chou WC
Pancreatology; 2024 Jun; 24(4):600-607. PubMed ID: 38565467
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
4. FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?
Bekaii-Saab T; Goldberg RM
Oncologist; 2013; 18(5):487-9. PubMed ID: 23704222
[No Abstract] [Full Text] [Related]
5. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.
Kipps E; Young K; Starling N
Ther Adv Med Oncol; 2017 Mar; 9(3):159-170. PubMed ID: 28344661
[TBL] [Abstract][Full Text] [Related]
6. When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.
Perez K; Clancy TE; Mancias JD; Rosenthal MH; Wolpin BM
J Clin Oncol; 2017 Feb; 35(5):485-489. PubMed ID: 28029328
[TBL] [Abstract][Full Text] [Related]
7. Current management and future directions in metastatic pancreatic adenocarcinoma.
Varghese AM; Lowery MA; Yu KH; O'Reilly EM
Cancer; 2016 Dec; 122(24):3765-3775. PubMed ID: 27649047
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Cancer: Progress in Systemic Therapy.
Perkhofer L; Ettrich TJ; Seufferlein T
Gastrointest Tumors; 2014 May; 1(4):167-79. PubMed ID: 26672477
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic adenocarcinoma: Beyond first line, where are we?
Cherri S; Noventa S; Zaniboni A
World J Gastroenterol; 2021 May; 27(17):1847-1863. PubMed ID: 34007126
[TBL] [Abstract][Full Text] [Related]
10. Current and future systemic treatment options in metastatic pancreatic cancer.
Arslan C; Yalcin S
J Gastrointest Oncol; 2014 Aug; 5(4):280-95. PubMed ID: 25083302
[TBL] [Abstract][Full Text] [Related]
11. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma.
Mehta A; Hwang WL; Weekes C
Ann Pancreat Cancer; 2020 May; 3():. PubMed ID: 33294843
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies in pancreas cancer.
Kotowski A; Ma WW
J Gastrointest Oncol; 2011 Jun; 2(2):93-103. PubMed ID: 22811835
[TBL] [Abstract][Full Text] [Related]
13. Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials.
Imperial R; Mosalem O; Majeed U; Tran NH; Borad MJ; Babiker H
Clin Exp Gastroenterol; 2024; 17():121-134. PubMed ID: 38650920
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer: New hopes after first line treatment.
Aroldi F; Bertocchi P; Savelli G; Rosso E; Zaniboni A
World J Gastrointest Oncol; 2016 Sep; 8(9):682-7. PubMed ID: 27672426
[TBL] [Abstract][Full Text] [Related]
15. Accomplishments in 2008 in the treatment of metastatic pancreatic cancer.
Heinemann V; Philip PA; Pelzer U
Gastrointest Cancer Res; 2009 Sep; 3(5 Supplement 2):S43-7. PubMed ID: 20011564
[TBL] [Abstract][Full Text] [Related]
16. Pancreas adenocarcinoma: novel therapeutics.
Krantz BA; Yu KH; O'Reilly EM
Chin Clin Oncol; 2017 Jun; 6(3):30. PubMed ID: 28705007
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.
Nguyen KT; Kalyan A; Beasley HS; Singhi AD; Sun W; Zeh HJ; Normolle D; Bahary N
J Gastrointest Oncol; 2017 Jun; 8(3):556-565. PubMed ID: 28736642
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
[TBL] [Abstract][Full Text] [Related]
19. Second line treatment options for pancreatic cancer.
Passero FC; Saif MW
Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
[TBL] [Abstract][Full Text] [Related]
20. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
